Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

MLA

Oh, Byeong-Chan, et al. “Survival Differences between Patients with de Novo and Relapsed/Progressed Advanced Non-Small Cell Lung Cancer without Epidermal Growth Factor Receptor Mutations or Anaplastic Lymphoma Kinase Rearrangements.” BMC Cancer, vol. 23, no. 1, May 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12885-023-10950-y.

APA

Oh, B.-C., Cho, A.-R., Nam, J. H., Yang, S.-Y., Kim, M. J., Kwon, S.-H., & Lee, E.-K. (2023). Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements. BMC Cancer, 23(1), 1–12. https://doi.org/10.1186/s12885-023-10950-y

Chicago

Oh, Byeong-Chan, Ae-Ryeo Cho, Jin Hyun Nam, So-Young Yang, Min Ji Kim, Sun-Hong Kwon, and Eui-Kyung Lee. 2023. “Survival Differences between Patients with de Novo and Relapsed/Progressed Advanced Non-Small Cell Lung Cancer without Epidermal Growth Factor Receptor Mutations or Anaplastic Lymphoma Kinase Rearrangements.” BMC Cancer 23 (1): 1–12. doi:10.1186/s12885-023-10950-y.